Global Congress on Prostate Cancer - PROSCA 2020

 

Global Congress on Prostate Cancer - PROSCA 2020
C

2020 Update on nmCRPC: Are Apalutamide, Darolutamide & Enzalutamide Equivalent? Does Denosumab Bone Targeted Therapy Prevent/Delay Bone Mets?

By Global Congress on Prostate Cancer - PROSCA 2020 FEATURING Charles Ryan
By Global Congress on Prostate Cancer - PROSCA 2020 FEATURING Charles Ryan
459 views
November 26, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss
Videos
17:52

2020 Update on MRI in PC: What Are the Guidelines for Delivering a H…

Global Congress on Prostate Cancer - PROSCA 2020

A. Padhani

166 views
16:06

2020 Updates on mHSPC: DT + RT, ADT + 6 Cycles Docetaxel, or Novel A…

Global Congress on Prostate Cancer - PROSCA 2020

U. Vogl

125 views
13:52

2020 Update on mCRPC: Which Patients Can Benefit From PARPi? Can Pre…

Global Congress on Prostate Cancer - PROSCA 2020

E. Castro

125 views
19:37

2020 Update on PSMA-PET in PC: Does It Make a Difference for Patient…

Global Congress on Prostate Cancer - PROSCA 2020

J. Calais

287 views
21:38

2020 Update on IO for Advanced PC: Is There an OS Benefit w/ Sipuleu…

Global Congress on Prostate Cancer - PROSCA 2020

P. Grivas

223 views
18:34

2020 Update on nmCRPC: Are Apalutamide, Darolutamide & Enzalutamide …

Global Congress on Prostate Cancer - PROSCA 2020

C. Ryan

459 views
17:06

2020 Update on MRI in Active Surveillance for PC: What Is the Aim, E…

Global Congress on Prostate Cancer - PROSCA 2020

J. Stranne

133 views
13:51

PC Robotic Radical Prostatectomy at Mount Sinai Health: How Does Hoo…

Global Congress on Prostate Cancer - PROSCA 2020

A. Tewari

44 views